<DOC>
	<DOCNO>NCT01226056</DOCNO>
	<brief_summary>Sorafenib oral multikinase inhibitor among target several RTKs involve tumor genesis ( Raf , Flt-3 , c-Kit RET ) angiogenesis ( VEGFR1 , 2 3 PDGFRß ) . Therefore sorafenib inhibits tumor growth dual mechanism , act either directly tumor ( inhibition Raf Kit signal ) and/or tumor angiogenesis ( inhibition VEGFR PDGFR signal . RAD001 novel derivative rapamycin . It selectively inhibit mTOR directly block tumor cell prevent tumor cell growth proliferation indirectly inhibit angiogenesis ( via potent inhibition HIF-1 consequently VEGF production ) . Targeting mTOR combination sorafenib might lead profound effect tumor cell biology could achieve individual targeting protein . New drug often meet limited success since always target pathway responsible tumor development growth target . To overcome problem , specific pathway target investigator two drug analyze single patient inclusion .</brief_summary>
	<brief_title>Sorafenib Combination With RAD001 Advanced Solid Tumors Selected Molecular Targets</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Patients progressive disease advance solid tumour judge non suitable standard treatment 2 . Biopsiable lesion archive tissue old 1 year assess expression : phosphorylated AKT phosphorylated p70S6 RKIP ( Raf Kinase Inhibitor Protein ) phosphorylated ERK1/2 The presence least one previous target mandatory patient enrolment 3 . At least 1 unidimensional measurable lesion accord modify RECIST 4 . Life expectancy least 12 week 5 . Age ≥ 18 year old 6 . ECOG Performance Status 0 1 7 . Adequate bone marrow , liver , renal function assess follow laboratory requirement conduct within 7 day prior start first dose : Haemoglobin ≥9.0 g/dL ( 5.6 mmol/L ) Absolute neutrophil count ( ANC ) ≥1.5 x 109/L Platelet count ≥100 x 109/L Total bilirubin ≤1.5 x upper limit normal ( ULN ) ALT AST ≤2.5 x ULN ( ≤5 x ULN patient liver involvement cancer ) Alkaline phosphatase ≤4 x ULN PTINR/PTT &lt; 1.5 x ULN Serum albumin level ≥2.5 mg/dl Serum creatinine ≤1.5 x ULN 8 . HBV/HCV test 2 week treatment start specific category patient hepatitis B C risk factor additional patient discretion investigator accord guideline Appendix 6 . 9 . All fertile patient must use adequate contraception study three subsequent month 10 . Ability understand willingness sign write informed consent . A sign informed consent must obtain prior perform study specific procedures 1 . History cardiac disease : congestive heart failure ( NYHA IIIV ) , active coronary artery disease CAD ( MI 6 month prior study entry allow ) , cardiac arrhythmia require antiarrhythmic therapy ( betablockers digoxin permit ) uncontrolled hypertension 2 . History HIV infection chronic hepatitis B C 3 . Patients NSCLC squamous histotype 4 . Recurrent hemoptysis cerebrovascular accident within 12 month , peripheral vascular disease claudication le 1 block ( 150 metre ) , history clinically significant bleed nontraumatic 5 . Deep venous thrombosis pulmonary embolus within 1 year ongoing need fulldose oral parenteral anticoagulation 6 . Clinically active infection ( &gt; Grade 2 NCICTC AE version 3.0 ) 7 . Evidence CNS tumor metastases 8 . History organ allograft 9 . Preexisting thyroid abnormality thyroid function maintain normal range medication 10 . Serious , nonhealing wound , ulcer , bone fracture 11 . Second malignancy within past 5 year ( except non melanoma skin cancer cervical carcinoma situ ) 12 . Pregnant breastfeeding patient 13 . Substance abuse , medical , psychological , social condition may interfere patient 's participation study evaluation study result 14 . Any condition unstable could jeopardize safety patient his/her compliance study 15 . Patients unable swallow oral medication 16 . Any malabsorption condition 17 . Prior treatment sorafenib mTOR inhibitor 18 . Ongoing requirement systemic corticosteroid medication immunosuppressant 19 . Radiotherapy within 3 week start study drug . Palliative radiotherapy allow . Major surgery within 4 week study entry 20 . Radiotherapy involve &gt; 30 % active bone marrow 21 . Autologous bone marrow transplant stem cell rescue within 4 month study entry 22 . Use biologic response modifier , GCSF , within 3 week study entry . Patients take chronic erythropoietin permit provide dose adjustment undertaken within 2 month prior study plan study period 23 . Investigational drug therapy outside trial within 4 week study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>advanced solid tumor</keyword>
	<keyword>Sorafenib ( Nexavar® )</keyword>
	<keyword>RAD001 ( everolimus )</keyword>
	<keyword>tumor molecular target</keyword>
</DOC>